DeGregorio M W, Maenpaa J U, Wiebe V J
University of California Cancer Center, Davis, Sacramento, USA.
Important Adv Oncol. 1995:175-85.
The tamoxifen chemoprevention trial in health women is ongoing in over 250 cancer treatment centers. The use of tamoxifen for the treatment of postmenopausal women with known breast cancer has been touted as a medical breakthrough by many physicians. However, the ongoing trial which enroll high-risk healthy women above the age of 34, has been controversial since its initiation in 1991. Congressional hearings, editorial, and statistical analyses concerning the scientific basis of the trial have emerged over the past year. This chapter presents the newest scientific facts, and speculates on the unknown risks of using tamoxifen as a chemopreventive in healthy women.
他莫昔芬在健康女性中的化学预防试验正在250多个癌症治疗中心进行。他莫昔芬用于治疗已知患有乳腺癌的绝经后女性，这一疗法被许多医生吹捧为医学上的一项突破。然而，这项始于1991年、招募34岁以上高危健康女性的试验，自启动以来就备受争议。在过去一年里，出现了关于该试验科学依据的国会听证会、社论和统计分析。本章介绍了最新的科学事实，并推测了在健康女性中使用他莫昔芬作为化学预防药物的未知风险。
